HHS: Bamlanivimab no longer distributed alone due to SARS-CoV-2 variant resistance

Given the sustained increase in variants resistant to bamlanivimab alone, and availability of alternative authorized monoclonal antibodies, the U.S. government, in coordination with Eli Lilly, will stop the distribution of bamlanivimab alone starting today, the Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response announced. Provider sites will still be able to order bamlanivimab/etesevimab, etesevimab alone to pair with existing stock of bamlanivimab on hand or REGEN COV following existing ordering and reporting procedures.

The Food and Drug Administration Friday updated the health care provider fact sheets for all three monoclonal antibody therapies authorized for emergency use to include information on whether SARS-CoV-2 variants may show resistance to that therapy.